Astria Therapeutics to Present at Upcoming Investment Conferences

Astria Therapeutics (NASDAQ:ATXS) has announced presentations at two upcoming investment conferences.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/06/2022 - 08:00 AM

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will be presenting at two upcoming investment conferences:

H.C. Wainwright 24^th Annual Global Investment Conference: Jill C. Milne, Ph.D., Chief Executive Officer at Astria will present a corporate overview and provide information on lead program STAR-0215. An on-demand webcast of the presentation can be accessed beginning at 7:00am ET on Monday, September 12, at the following link: https://journey.ct.events/view/aef48288-dfa2-462a-b6ec-9b593a73d637.
Ladenburg Thalmann 2022 Healthcare Conference: On September 29, Dr. Milne will present during a fireside chat at 1:30pm ET. A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/ladenburg8/atxs/2450816.

Archived replays of the presentations will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.